Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity
The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.
Primary source
ClinicalTrials.gov registry record, November 12, 2026
The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight
Read the source: The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation